Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
29 hedge funds and large institutions have $18.2M invested in Cymabay Therapeutics in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
4% more funds holding
Funds holding: 28 → 29 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
68% less capital invested
Capital invested by funds: $56.7M → $18.2M (-$38.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$821K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$190K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$155K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$103K |
| 5 |
JP Morgan Chase
New York
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$2.34M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.36M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.09M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$1.07M |
| 5 |
VAM
Visium Asset Management
New York
|
-$833K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $7K | -$352K | -85,603 | -97% |
|
27
Bank of America
Charlotte,
North Carolina
| $6K | +$9.04K | +2,200 | New |
|
|
BIM
28
BlackRock Investment Management
Wilmington,
Delaware
| $6K | +$9.2K | +2,239 | New |
|
29
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1 | – | – | – |
|
|
SFM
30
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.09M | -157,179 | Closed |
|
31
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$374K | -54,108 | Closed |
|
32
Acadian Asset Management
Boston,
Massachusetts
| – | -$211K | -30,383 | Closed |
|
33
Citadel Advisors
Miami,
Florida
| – | -$183K | -26,373 | Closed |
|
|
JG
34
Jefferies Group
New York
| – | -$150K | -21,646 | Closed |
|
|
EEG
35
E.E. Geduld
| – | -$138K | -20,000 | Closed |
|
|
MC
36
Menta Capital
San Francisco,
California
| – | -$127K | -18,356 | Closed |
|
|
EGA
37
Eagle Global Advisors
Houston,
Texas
| – | -$115K | -16,630 | Closed |
|
CBAY Hedge Fund Activity: Q2 2015 in Review
29 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2015, worth a combined $18.2M — down 68% from $56.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CBAY positions and 8 closed out — a net gain of 1 holder — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $821K. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $2.34M.
- 29 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2015, up from 28 in Q1 2015.
- Funds reported $18.2M of Cymabay Therapeutics stock for Q2 2015, down 68% quarter-over-quarter.
- 9 funds opened new Cymabay Therapeutics positions in Q2 2015 and 8 closed out, a net change of +1 holder.
- The largest Cymabay Therapeutics buyer in Q2 2015 was Pura Vida Investments, an estimated $821K added.
- The largest Cymabay Therapeutics seller in Q2 2015 was Lombard Odier Asset Management (USA), an estimated $2.34M sold.
Based on aggregated 13F filings for Q2 2015.